This duality positions NLRP3 as a therapeutic target, where inhibition could attenuate pro-tumorigenic signaling in inflammation-driven cancers or enhance pyroptosis in malignancies where inflammasome activation is tumor suppressive. The gene discussed is NLRP3; the disease is cancer.